From The Advisory Board
This article reviews the current evidence for the role of aromatase inhibitors (AIs) in the treatment of advanced stage or recurrent endometrial cancer.
Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.
Steven J. Cohen, MD, CTA Advisory Board member highlights key science from the 2015 Gastrointestinal Cancer Symposium.
CTA Advisory Board member, Neal Shore, MD, puts CHAARTED trial results into context.
Dr. Jeffrey Farma provides his insight on treating the elderly patient population in the surgical oncology setting.
Oncologists who care for non-small cell lung cancer (NSCLC) patients need to develop management strategies.
Immune therapies hold substantial promise to improve therapeutic options for patients with metastatic renal cancer.
Dr. Dizon and patient advocate Katherine O'Brien discuss the difficulty of communicating cancer and give advice on common miscommunications.
Dr. Burtness, a member of the Cancer Therapy Advisory Board, reflects on the loss of Dr. Abraham Borbor, the only certified internist in Liberia who recently died of Ebola.
ChemotherapyAdvisor.com Editorial Board Member Don S. Dizon discusses survivorship issues from the 2013 Breast Cancer Symposium.
Editorial Advisory Board member Dr. Socinski discusses the key clinical insights brought to light by the POINTBREAK trial, presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
An expert reviews the new maintenance, second- and third-line therapies for colorectal cancer treatment presented at the 2013 Gastrointestinal Cancers Symposium.
In this article, Advisory Board member Neal Shore, MD, FACS, discusses barriers to clinicians recommending active surveillance for men with low-risk prostate cancer.
Several new therapies for metastatic colorectal cancer have been developed and refined, changing the way the disease can be treated.
Advisory Board Member Dr. Farma reviews the current recommendations for using sentinel lymph node biopsy in patients with melanoma.
This patient, who had an increasing PSA level, was found to have abnormal PCA3 urine test results.
Advisory Board member Neal D. Shore, MD, FACS relates how vital it is that urologists recognize the changing demands of the field.
Dr. Steven Cohen comments on the 2012 ASCO Annual Meeting and the standard of care for gastrointestinal malignancies.
Dr. Perez comments on the 2012 ASCO Annual Meeting and the standard of care for breast malignancies.
Initial salvage treatment with allogenic stem cell transplant (ASCT) is feasible and yields superior outcomes to salvage chemotherapy in acute myeloid leukemia (AML) patients.
Dr. E. David Crawford, Head Urologic Oncology at the University of Colorado, presents his case study on renal cell carcinoma (RCC).
Although there are new therapies for M1CRPC patients and others pending, ideal sequencing regimen is still not certain.
Although prevalence of cytogenetic abnormality in tumor biopsy is low, finding one or more abnormalities can expand the patient's treatment options.
Dr. E. David Crawford, an internationally renowned expert in the treatment of metastatic castrate resistant prostate cancer, offers his predictions about emerging treatment options and how they will fit into the current regimens.
The optimal treatment of multiple myeloma today requires a multidisciplinary approach. The advent of novel therapeutic agents has opened new avenues of therapy, which although extremely effective, can be associated with significant toxicities. A team approach to treatment of the multiple myeloma patient goes a long way in reducing the potential for serious complications during induction and consolidation therapy.
Approximately 80% of patients with bladder cancer present with non-muscle-invasive disease (NMIBC). Of these, 15 to 25% will eventually develop muscle-invasive bladder cancer, and there are a number of known predictors of progression to invasive disease.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy